CMO’s Zero‑Cost Option Surge Signals Bold Confidence Amid Radiopharm’s Risk‑Heavy Future
Voliotis Dimitris’s zero‑cost option buy shows top‑level confidence in Radiopharm’s risky biotech, backed by a fresh $8 M Rockford Capital advance.
3 minutes to read